CAR-macrophages in solid tumors: promise, progress, and prospects

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• Chimeric antigen receptor macrophages (CAR-Ms) are an emerging immunotherapy approach for solid tumors.
• CAR-Ms combine innate immune functions with engineered CAR signaling for direct tumor targeting and microenvironment modulation.
• Existing cell-based therapies face limitations, highlighting the need for novel strategies like CAR-Ms.

Purpose of the Study:

• To review recent advancements in CAR-M therapy for solid tumors.
• To discuss the biological rationale and preclinical findings supporting CAR-M efficacy.
• To identify technological innovations required for successful clinical translation of CAR-Ms.

Main Methods:

• Review of preclinical and clinical evidence on CAR-M therapy.
• Analysis of biological mechanisms of CAR-Ms in solid tumors.
• Discussion of technological challenges and innovations in CAR-M development.

Main Results:

• Preclinical and clinical data indicate significant promise for CAR-M therapy in solid tumors.
• CAR-Ms demonstrate potential to actively remodel the tumor microenvironment.
• CAR-Ms offer direct tumor cell targeting via CAR signaling.

Conclusions:

• CAR-M therapy is a promising immunotherapy strategy for solid tumors.
• Clinical translation is hindered by challenges in cell expansion, genetic engineering, and product quality.
• Technological innovations are crucial for developing CAR-Ms as a versatile, off-the-shelf immunotherapy for difficult-to-treat solid malignancies.